Sign up USA
Proactive Investors - Run By Investors For Investors

VentriPoint Diagnostics gets gateway CE mark

Toronto-listed medtech firm VentriPoint Diagnostics Ltd (CVE:VPT) has announced a major step forward for its breakthrough whole heart analysis system - a European CE mark. Dr.George Adams, CEO, tells Proactive how this is a 'gateway' moment to other markets worldwide with hypertension becoming a critical health epidemic and the leading cause of death among Western nations.. The group's VMSplus device can now be sold to aid in-heart treatment throughout the European Union. Shares surged almost 22% in Toronto to C$0.39. As the definition of hypertension has also recently been changed, governments and health providers across the world are now keen to identify the risk early and treat the condition, rather than let it go undiagnosed which often leads to expensive surgery.

Meet Mineworx Technologies Ltd. and Transition Metals Corp at our event, New York , 24 October 2018. Register here »
View full VPT profile View Profile

VentriPoint Diagnostics Ltd. Timeline

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use